Skip to main content

Table 7 Prior to propensity score matching, neuromuscular blocking agent (NMBA) treatment, defined as 3 days of continuous use of NMBAs, within 48 h from commencement of invasive mechanical ventilation, was associated with 90-day mortality (unadjusted Cox regression; HR 2.13, 95% CI 1.40, 3.24, P < 0.001). After propensity-score matching, 50 patients who received NMBA treatment were matched with 50 controls (using replacement). Using the propensity score-matched cohort (and adjusting for covariates as per Table 4, NMBA therapy was not associated with 90-day mortality (adjusted HR 1.56 95% CI 0.55, 4.32, P = 0.392)

From: Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

 

Propensity score-matched cohort

(N = 100)

90-day mortality from ICU admission

Control

(N = 50)

NMBA treatment

(N = 50)

Total

(N = 100)

Survived

38 (76%)

33 (66%)

71 (71%)

Died

12 (24%)

17 (34%)

29 (29%)

Total

50

50

100